143 related articles for article (PubMed ID: 38214731)
1. [Iatrogenic retinal defects after intravitreal operative drug injections].
Märker DA; Radeck V; Lehmann F; Barth T; Helbig H; Eter N; Alten F; Clemens CR
Ophthalmologie; 2024 Feb; 121(2):129-134. PubMed ID: 38214731
[TBL] [Abstract][Full Text] [Related]
2. [Lens injury as a complication of intravitreal medication injection].
Clemens CR; Alten F; Eter N; Helbig H; Märker DA
Ophthalmologie; 2024 May; 121(5):385-390. PubMed ID: 38363379
[TBL] [Abstract][Full Text] [Related]
3. [Complications of intravitreal injections--own experience].
Jamrozy-Witkowska A; Kowalska K; Jankowska-Lech I; Terelak-Borys B; Nowosielska A; Grabska-Liberek I
Klin Oczna; 2011; 113(4-6):127-31. PubMed ID: 21913440
[TBL] [Abstract][Full Text] [Related]
4. Safety study of 38,503 intravitreal ranibizumab injections performed mainly by physicians in training and nurses in a hospital setting.
Hasler PW; Bloch SB; Villumsen J; Fuchs J; Lund-Andersen H; Larsen M
Acta Ophthalmol; 2015 Mar; 93(2):122-5. PubMed ID: 25403735
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal bevacizumab for iatrogenic choroidal neovascular membrane following vitreoretinal surgery for retinal detachment.
Appanraj R; Duraiswamy H; Saravanan V; Manayath G; Venkatapathy N
Indian J Ophthalmol; 2020 Jun; 68(6):1201-1203. PubMed ID: 32461482
[TBL] [Abstract][Full Text] [Related]
6. Frequency of Rhegmatogenous Retinal Detachment after Intravitreal Therapy in Neovascular Age-Related Macular Degeneration.
Mammo DA; Ringeisen AL; Parke DW
Ophthalmol Retina; 2020 Oct; 4(10):973-978. PubMed ID: 32651157
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C
J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
[TBL] [Abstract][Full Text] [Related]
8. Retinal tears and rhegmatogenous retinal detachment after intravitreal injections: its prevalence and case reports.
Karabag RY; Parlak M; Cetin G; Yaman A; Osman Saatci A
Digit J Ophthalmol; 2015; 21(1):8-10. PubMed ID: 27330458
[TBL] [Abstract][Full Text] [Related]
9. Iatrogenic Retinal Penetration from Intravitreal Injections.
Kishore K; McGowan DS; Hanebrink KA
Case Rep Ophthalmol; 2021; 12(1):248-253. PubMed ID: 33976691
[TBL] [Abstract][Full Text] [Related]
10. [Intravitreal triamcinolone acetonide for the treatment of intraocular edematous and neovascular diseases].
Jonas JB; Kreissig I; Kamppeter B; Degenring RF
Ophthalmologe; 2004 Feb; 101(2):113-20. PubMed ID: 14991306
[TBL] [Abstract][Full Text] [Related]
11. Safety of 6000 intravitreal dexamethasone implants.
Rajesh B; Zarranz-Ventura J; Fung AT; Busch C; Sahoo NK; Rodriguez-Valdes PJ; Sarao V; Mishra SK; Saatci AO; Udaondo Mirete P; Querques G; Farah ME; Lanzetta P; Arevalo JF; Kodjikian L; Chhablani J;
Br J Ophthalmol; 2020 Jan; 104(1):39-46. PubMed ID: 31040132
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal triamcinolone acetonide: a change in a paradigm.
Jonas JB
Ophthalmic Res; 2006; 38(4):218-45. PubMed ID: 16763379
[TBL] [Abstract][Full Text] [Related]
13. [Technique of intravitreal drug injection for therapy of vitreoretinal diseases].
Rodrigues EB; Maia M; Penha FM; Dib E; Bordon AF; Magalhães Júnior O; Farah ME
Arq Bras Oftalmol; 2008; 71(6):902-7. PubMed ID: 19169531
[TBL] [Abstract][Full Text] [Related]
14. Rhegmatogenous Retinal Detachment after Intravitreal Injection.
Brown KR; Yannuzzi NA; Smiddy WE; Gregori NZ; Berrocal AM; Haddock LJ; Schwartz SG; Lee WH; Sridhar J; Wu DM; Flynn HW; Townsend JH
Ophthalmol Retina; 2021 Feb; 5(2):178-183. PubMed ID: 32673672
[TBL] [Abstract][Full Text] [Related]
15. DEXAMETHASONE INTRAVITREAL IMPLANT FOR THE TREATMENT OF RECALCITRANT MACULAR EDEMA AFTER RHEGMATOGENOUS RETINAL DETACHMENT REPAIR.
Thanos A; Todorich B; Yonekawa Y; Papakostas TD; Khundkar T; Eliott D; Dass AB; Williams GA; Capone A; Faia LJ; Wolfe JD; Hassan TS; Ruby AJ
Retina; 2018 Jun; 38(6):1084-1090. PubMed ID: 28622270
[TBL] [Abstract][Full Text] [Related]
16. Surveillance for potential adverse events associated with the use of intravitreal bevacizumab for retinal and choroidal vascular disease.
Wong LJ; Desai RU; Jain A; Feliciano D; Moshfeghi DM; Sanislo SR; Blumenkranz MS
Retina; 2008 Oct; 28(8):1151-8. PubMed ID: 18685542
[TBL] [Abstract][Full Text] [Related]
17. [Outcome after vitrectomy in rhegmatogenous retinal detachment and dense vitreous opacities].
Hoerauf H; Roider J; Herboth T; Hager A; Laqua H
Klin Monbl Augenheilkd; 1997 Dec; 211(6):369-74. PubMed ID: 9498187
[TBL] [Abstract][Full Text] [Related]
18. Ocular morbidity associated with intravitreal triamcinolone acetonide.
Konstantopoulos A; Williams CP; Newsom RS; Luff AJ
Eye (Lond); 2007 Mar; 21(3):317-20. PubMed ID: 16710433
[TBL] [Abstract][Full Text] [Related]
19. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
[TBL] [Abstract][Full Text] [Related]
20. Incidence of rhegmatogenous retinal detachments after intravitreal antivascular endothelial factor injections.
Meyer CH; Michels S; Rodrigues EB; Hager A; Mennel S; Schmidt JC; Helb HM; Farah ME
Acta Ophthalmol; 2011 Feb; 89(1):70-5. PubMed ID: 21176118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
